PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients

Clinics

Volumn 67, Issue 11, 2012, Pages 1285-1290

  Mangone, Flavia R ^a   Bobrovnitchaia, Irina G ^a   Salaorni, Sibeli ^a   Manuli, Erika ^a   Nagai, Maria A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Breast neoplasm; Mutation; PIK3CA; Prognosis; TP53

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; SIGNAL PEPTIDE;

ADULT; AGED; ARTICLE; BRAZIL; BREAST TUMOR; EPIDEMIOLOGY; EXON; FEMALE; GENETICS; HUMAN; MIDDLE AGED; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BRAZIL; BREAST NEOPLASMS; EPIDEMIOLOGIC METHODS; EXONS; FEMALE; GENES, P53; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION;

EID: 84870442653     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(11)11     Document Type: Article

References (21)

1. Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, et al. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle. 2009;8(9):1352-1358, http://dx.doi.org/10.4161/cc.8.9.8255.
2. Ciraolo E, Morello F, Hirsch E. Present and future of PI3K pathway inhibition in cancer: perspectives and limitations. Curr Med Chem. 2011;18(18):2674-2685, http://dx.doi.org/10.2174/092986711796011193.
3. Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol. 2010;347:21-41, http://dx.doi.org/10.1007/82_2010_68.
4. Murugan AK, Hong NT, Fukui Y, Munirajan AK, Tsuchida N. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int J Oncol. 2008;32(1):101-111.
5. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol. 2006;18(1):77-82, http://dx.doi.org/10.1097/01.cco.0000198021.99347.b9.
6. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009;4:127-150.
7. Castaneda CA, Cortes-Funes H, Gomez HL, Ciruelos EM. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Metastasis Rev. 2010;29(4):751-759, http://dx.doi.org/10.1007/s10555-010-9261-0.
8. Liedtke C, Cardone L, Tordai A, Yan K, Gomez HL, Figureoa LJ, et al. PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res. 2008;10(2):R27, http://dx.doi.org/10.1186/bcr1984.
9. Dupont Jensen J, Laenkholm AV, Knoop A, Ewertz M, Bandaru R, Liu W, et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res. 2011;17(4):667-677, http://dx.doi.org/10.1158/1078-0432.CCR-10-1133.
10. V Ching-Shian, Leong V, Jabal MF, Leong PP, Abdullah MA, Gul YA, Seow HF. PIK3CA gene mutations in breast carcinoma in Malaysian patients. Cancer Genet Cytogenet. 2008;187(2):74-79, http://dx.doi.org/10.1016/j.cancergencyto.2008.07.005.
11. Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res. 2007;13(2PT 1):408-414, http://dx.doi.org/10.1158/1078-0432.CCR-06-0267.
12. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008; 68(15):6084-6091, http://dx.doi.org/10.1158/0008-5472.CAN-07-6854.
13. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res. 2009;15(16):5049-5059, http://dx.doi.org/10.1158/1078-0432.CCR-09-0632.
14. Li SY, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat. 2006;96(1):91-95, http://dx.doi.org/10.1007/s10549-005-9048-0.
15. Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res. 2007;13(20):6064-6069, http://dx.doi.org/10.1158/1078-0432.CCR-07-0266.
16. Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH, Tzen CY. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol. 2008;15(4):1064-1069, http://dx.doi.org/10.1245/s10434-007-9751-7.
17. Nagai MA, Schaer Barbosa H, Zago MA, Araújo Silva W Jr, Nishimoto IN, Salaorni S, et al. TP53 mutations in primary breast carcinomas from white and African-Brazilian patients. Int J Oncol. 2003;23(1):189-196.
18. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005;65(7):2554-2559, http://dx.doi.org/10.1158/0008-5472-CAN-04-3913.
19. Boyault S, Drouet Y, Navarro C, Bachelot T, Lasset C, Treilleux I, et al. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat. 2012;132(1):29-39, http://dx.doi.org/10.1007/s10549-011-1518-y.
20. Michelucci A, Di Cristofano C, Lami A, Collecchi P, Caligo A, Decarli N, et al. PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases. Diagn Mol Pathol. 2009;18(4):200-205, http://dx.doi.org/10.1097/PDM.0b013e31818e5fa4.
21. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318(5853):1108-1113, http://dx.doi.org/10.1126/science.1145720.